Privacy Policy

Privacy Policy (Effective April 2023)

Anagram Therapeutics recognizes the importance of protecting the privacy of information we may receive from visitors to our website (this “website” or the “site”). This Privacy Policy describes the information we collect from visitors to this website, how we may use and with whom we may share that information, the safeguards we use to protect such information and the choices you may make with respect to your personal information.

Information You Provide Through the Site

If you contact us and choose to provide personally identifiable information or other personal data, such as your name, address, telephone number or email address, we will utilize it for the purpose for which you submitted it to us, such as to respond to your inquiry or to provide you with the information you have requested. By voluntarily providing us with your personal data, you are consenting to our use of it in accordance with this Privacy Policy. The only personal data Anagram Therapeutics currently collects through this website is the information you send to us when (i) you contact Anagram Therapeutics with your questions or comments through the Contact page on this website or (ii) when you complete a sign-up form to learn more about a clinical trial or medical condition for which Anagram Therapeutics is developing a treatment.

We do not collect or maintain personally identifiable information for resale purposes, or share your information with any other company or organization, except as indicated above or to the extent such other company or organization is acting as our agent for processing or mailing purposes to assist us in providing information that you have requested. In addition, we will not send unsolicited messages to users of our site who indicate that they do not wish to receive such messages.

Legal Requirements

We reserve the right to disclose your personal information (i) as required by law, court order, legal process or government or regulatory requirement or (ii) to protect the safety, rights, or property of the public or Anagram Therapeutics.

This is an example of a bulleted list:

This is an example of a numbered list:

  1. The term “investigator” means the project director or principal investigator and any other person, regardless of title or position, who is responsible for the design, conduct, or reporting of research funded by the PHS, or proposed for such funding, which may include, for example, collaborators or consultants.
  2. The term “research” means a systematic investigation, study or experiment designed to develop or contribute to generalizable knowledge relating broadly to public health, including behavioral and social-sciences research. The term encompasses basic and applied research (e.g., a published article, book or book chapter) and product development (e.g., a diagnostic test or drug). The term includes any such activity for which research funding is available from a PHS Awarding Component through a grant or cooperative agreement.
  3. The term “institutional responsibilities” means an investigator's professional responsibilities on behalf of Anagram, including research, research consultation, clinical or other professional practice, participation in scholarly events, institutional committee memberships; and service on panels such as Institutional Review Boards or Data and Safety Monitoring Boards.
  4. The term “significant financial interest” means a financial interest - defined as anything of monetary value, whether or not readily ascertainable - consisting of one or more of the following interests of the investigator (and those of the investigator's spouse and dependent children) that reasonably appears to be related to the investigator's institutional responsibilities.